Skip to content
Clinical Trials – home
NorwayBack to Norway

Clinical trials in Skedsmokorset – page 27

607 clinical trials in Skedsmokorset, Norway. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Skedsmokorset at a glance
607
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

607 trials in Skedsmokorset

Open in trial search

Study on the Effect of Xylometazoline Nasal Spray on Physical Capacity in Adults with Chronic Obstructive Pulmonary Disease (COPD)

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · Healthy volunteers
  • Substances:Xylometazoline hydrochloride
  • Sponsor:Sorlandet Sykehus HF

Varicella

Not yet recruiting

Study on the Immune Response and Safety of a Second Dose of Investigational Varicella Vaccine (GSKVX000000025896) Compared to Varicella Virus Oka/Merck Strain in Healthy Children

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · Healthy volunteers
  • Substances:GSKVX000000025896
  • Sponsor:GlaxoSmithKline Biologicals

Study on the Effectiveness and Safety of Masitinib with Riluzole for Patients with Amyotrophic Lateral Sclerosis (ALS)

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Masitinib
  • Sponsor:Ab Science

Anal cancer

Not yet recruiting

Study of Pembrolizumab with Standard Chemoradiation for Patients with Advanced Anal Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Cardiff University

Cholangitis sclerosing

Not yet recruiting

Study on the Safety and Tolerability of Norucholic Acid Tablets for Patients with Primary Sclerosing Cholangitis (PSC)

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Norucholic Acid
  • Sponsor:Dr. Falk Pharma GmbH

Colitis ulcerative

Not yet recruiting

Study on the Safety and Effectiveness of Lutikizumab and Adalimumab for Adults with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Systemic lupus erythematosus+1

Not yet recruiting

Study on the Effects of Rapcabtagene Autoleucel in Patients with Systemic Lupus Erythematosus and Active, Refractory Lupus Nephritis

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Novartis Pharma AG

Colorectal cancer

Not yet recruiting

Study on Acetylsalicylic Acid for Colorectal Cancer Patients with PI3K Pathway Mutations

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Karolinska Institutet

Lichen planopilaris

Not yet recruiting

Study on Treating Frontal Fibrosing Alopecia in Adults Using Microneedling and Photodynamic Therapy with Methyl Aminolevulinate Hydrochloride

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Methyl Aminolevulinate Hydrochloride
  • Sponsor:Oslo University Hospital HF

Non-small cell lung cancer

Not yet recruiting

Study to Compare Zongertinib with Standard Treatment for Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Metastases to peritoneum

Not yet recruiting

Study of Radspherin® for Patients with Peritoneal Cancer from Colorectal Cancer After Surgery and Chemotherapy

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:RADIUM-224 adsorbed in calcium carbonate microparticles
  • Sponsor:Oncoinvent ASA

Nephrogenic anaemia

Not yet recruiting

Study on Roxadustat for Treating Anemia in Children with Chronic Kidney Disease

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years
  • Substances:Darbepoetin Alfa
  • Sponsor:Astellas Pharma Global Development Inc.

Other cities in Norway

The busiest research cities in the country

All 53 cities in Norway

Clinical research in Skedsmokorset

What the registry says about research in the country

01 Cardiovascular Research

Innovative clinical trials focusing on lipoprotein management and prevention of major cardiovascular events in patients with established cardiovascular disease.

  • Cardiovascular Disease Prevention
  • Lipid Management
  • Cardiovascular Event Reduction

Studies evaluating novel therapeutic approaches for reducing cardiovascular mortality and improving patient outcomes.

02 Stroke Prevention

Research examining new treatments for preventing stroke and systemic embolism in patients with atrial fibrillation, comparing innovative therapies with established medications.

  • Atrial Fibrillation Management
  • Anticoagulation Therapy
  • Stroke Risk Reduction

Trials focused on developing safer and more effective treatments for stroke prevention.

03 Vascular Disease Research

Studies investigating treatments for atherosclerotic cardiovascular disease, with emphasis on preventing major adverse cardiovascular events.

  • ASCVD Management
  • Cardiovascular Risk Reduction
  • LDL cholesterol Control

Evaluation of novel therapies targeting established vascular disease and its complications.

04 Pulmonary Medicine

Clinical research examining the effectiveness of combination therapies for Chronic Obstructive Pulmonary Disease, focusing on cardiopulmonary outcomes.

  • COPD Treatment
  • Respiratory Medicine
  • Bronchodilator Therapy

Investigation of advanced treatment options for improving respiratory function and quality of life.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.